The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies.
C. Lin
No relevant relationships to disclose
W. Su
No relevant relationships to disclose
C. Yen
No relevant relationships to disclose
A. Cheng
No relevant relationships to disclose
Y. Lu
No relevant relationships to disclose
C. Hsu
No relevant relationships to disclose
W. Su
No relevant relationships to disclose
D. C. Huang
Employment or Leadership Position - Boehringer Ingelheim
H. Fritsch
Employment or Leadership Position - Boehringer Ingelheim
F. Voss
Employment or Leadership Position - Boehringer Ingelheim
R. Schreck
Employment or Leadership Position - Boehringer Ingelheim
T. Taube
Employment or Leadership Position - Boehringer Ingelheim
C. Yang
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim